

Meeting Invitees:

X	Dr. Nicholas Antos		Kevin Josephson		Darci Pfeil
X	Dr. Mei Baker	X	Alison LaPean-Kirschner	X	Dr. Mike Rock
	Nicole Brueck	X	Dr. Jennifer Kwon		Erin Seffrood
X	Anna Cisler		Mary Marcus		Tammi Timmler
X	Sumehda Ghate		Tami Miller		
	Dr. Matthew Harmelink	X	Peggy Modaff		
	Dr. Peter Holzwarth		Dr. Julie Noe		Students:
X	Tami Horzewski				

Agenda:

Friday, 1	November 1:	5, 1:00PM	-3:00 I	PM
	WSLH -	Ag Drive		

Time:	Topic:	Lead:	Follow-up Items:	Notes:
1:00 PM – 3:00 PM	Welcome and Review of Minutes	Dr. Antos		Motion to approve April 1, 2019 minutes: 1st Motion: Dr. Kwon 2nd Motion: Sumehda Ghate Motion approved. Multiple presentations were given in the past year on our Next Gen Sequencing experience, including Drs. Rock & Baker presented at the European CF Conference and Drs. Antos & Baker at NACFC
	DHS Updates	Tami Horzewski		The following DHS updates were shared: • Spinal Muscular Atrophy (SMA) and Carnitine Palmitoyltransferase IA



	(CPT IA) deficiency were approved by emergency rule on October 15, 2019 and are moving through the process to be put into permanent rule to become a part of the Newborn Screening (NBS) panel. Pompe Disease has been nominated for addition to the NBS panel of conditions and will be considered at the upcoming Umbrella Committee meeting on December 6th. The Pompe Disease nomination was reviewed by the metabolic subcommittee at their last meeting and was recommended for addition to the panel. Dr. Gary Kirk is resigning as the Chief Medical Officer at the Department of Health Services and his last day will be December 13th.



Minutes

2018 Screening Summary		(Cystic fibrosis screening 201	.8:
	Dr. Baker		Screened Infants Born in 2018	63,524
		-	Reported Screening Positive w/ Two Variants	46
			Reported Screening Positive w/ one Variant	173
			Confirmed CF Cases	15
			PPV	6.8%
			Incidence	1 in 4,235
			More detailed information handled in attached slides.	as been
Request for Parental CFTR NGS Assay	Dr. Baker	that CFT	Baker reminded the committ the time frame for requesting R NGS assay is within 6 mo- ening positive report.	g parental
Request for NGS Data Re-Analysis	Dr. Baker	cour data the l	committee members agreed aselors can request CFTR NO re-analysis on behalf of clin ab report will reflect such prordingly.	GS assay icians, and
SMA NBS Implementation	Dr. Baker	scree	NBS lab at WSLH impleme ening on 10/15/2019. As of 0 infants have been screened	11/14/2019,



		One screening positive case was reported, and later confirmed as a true positive case.
MVCC Screening Discussion, including 5T •Discuss the current state of MVCC screening, processes, concerns, findings, and options	Dr. Antos/Alison LaPean-Kirschner/ Dr. Baker/ Sumedha Ghate	The process for screening for MVCC was discussed at length. Concerns included specifically the mutation 5T 11TG and compound heterozygotes with a normal sweat test. Multiple options for screening were discussed, as in the attached images. It was agreed that the process would change to checking MVCC only after a borderline/abnormal sweat test, as part of the unblinding. It was agreed that we will update our CF-causing variant panel based on the version of "11March2019" posted on the CFTR2 website. Current state and proposed state are pictured below and in the full slides. The feasibility and appropriateness of this was agreed on by clinical, genetic, and laboratory team members. 1st motion: Dr. Antos 2nd motion: Alison LaPean-Kirschner Dr. Baker proposed start date — January 1, 2020



		Discussed and approved protocol for the patients already identified. In summary, we will continue to follow ~yearly until about 5 years old and continue to reassess the process. Full protocol will be sent to CF Teams.
Plan Next Meeting/Agenda Items	All	Tami will work with Dr. Antos and Dr. Baker to determine a potential date for the next meeting in April, 2020 and then send out the meeting date options to the subcommittee.



